Search results for abx831323

Obexelimab, Abbexa, abx831323

Obexelimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD19, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Obexelimab (XmAb5871) is a first-in-class monoclonal antibody that targets CD19 with its variable domain and uses the XmAb immune inhibitory Fc domain to target FcγRIIb, a receptor that inhibits B cell function. Obexelimab is the first drug candidate to our knowledge that targets FcγRIIb inhibition.